Cargando…

Cross-Reactivity of IgG Antibodies and Virus Neutralization in mRNA-Vaccinated People Against Wild-Type SARS-CoV-2 and the Five Most Common SARS-CoV-2 Variants of Concern

The rapid development, approval, and production of vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in less than 1 year after the first reports of a new infectious disease was a real game changer, providing 80%–90% efficacy in preventing severe etiopathologies of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwarze, Mandy, Krizsan, Andor, Brakel, Alexandra, Pohl, Fabian, Volke, Daniela, Hoffmann, Ralf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9242094/
https://www.ncbi.nlm.nih.gov/pubmed/35784285
http://dx.doi.org/10.3389/fimmu.2022.915034
_version_ 1784737979664695296
author Schwarze, Mandy
Krizsan, Andor
Brakel, Alexandra
Pohl, Fabian
Volke, Daniela
Hoffmann, Ralf
author_facet Schwarze, Mandy
Krizsan, Andor
Brakel, Alexandra
Pohl, Fabian
Volke, Daniela
Hoffmann, Ralf
author_sort Schwarze, Mandy
collection PubMed
description The rapid development, approval, and production of vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in less than 1 year after the first reports of a new infectious disease was a real game changer, providing 80%–90% efficacy in preventing severe etiopathologies of the coronavirus disease 2019 (COVID-19). These vaccines induce an immune response against the SARS-CoV-2 spike (S) protein located on the surface of the virus particle. Antibodies (Abs) recognizing the S-protein can inhibit binding of the virus via the S-protein to the angiotensin-converting enzyme-2 (ACE-2) receptor expressed on different human cells, especially when these Abs bind to the interaction site, the so-called receptor-binding domain (RBD). We have expressed the RBDs of wild-type SARS-CoV-2 and five variants of concern (VOCs) to test the immune response in people before vaccination with mRNA vaccines BNT162b2 and mRNA-1273 and after up to three vaccinations using in-house ELISA and inhibition assays. The methods of both assays are provided. Both vaccines initiated similarly high IgG titers after two vaccinations against the wild-type and even two VOC-RBDs (alpha and delta) and strongly inhibited the corresponding RBD-ACE-2 binding. The IgG titers and inhibition of ACE-2 binding were lower for beta and gamma RBDs and much lower for omicron RBD. The third vaccination after 6 months strongly increased both the IgG titers and the neutralizing effect against all variants, especially for omicron, leading to 63% ± 13% neutralization potential. Importantly, neutralization linearly increased with the IgG titers.
format Online
Article
Text
id pubmed-9242094
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-92420942022-06-30 Cross-Reactivity of IgG Antibodies and Virus Neutralization in mRNA-Vaccinated People Against Wild-Type SARS-CoV-2 and the Five Most Common SARS-CoV-2 Variants of Concern Schwarze, Mandy Krizsan, Andor Brakel, Alexandra Pohl, Fabian Volke, Daniela Hoffmann, Ralf Front Immunol Immunology The rapid development, approval, and production of vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in less than 1 year after the first reports of a new infectious disease was a real game changer, providing 80%–90% efficacy in preventing severe etiopathologies of the coronavirus disease 2019 (COVID-19). These vaccines induce an immune response against the SARS-CoV-2 spike (S) protein located on the surface of the virus particle. Antibodies (Abs) recognizing the S-protein can inhibit binding of the virus via the S-protein to the angiotensin-converting enzyme-2 (ACE-2) receptor expressed on different human cells, especially when these Abs bind to the interaction site, the so-called receptor-binding domain (RBD). We have expressed the RBDs of wild-type SARS-CoV-2 and five variants of concern (VOCs) to test the immune response in people before vaccination with mRNA vaccines BNT162b2 and mRNA-1273 and after up to three vaccinations using in-house ELISA and inhibition assays. The methods of both assays are provided. Both vaccines initiated similarly high IgG titers after two vaccinations against the wild-type and even two VOC-RBDs (alpha and delta) and strongly inhibited the corresponding RBD-ACE-2 binding. The IgG titers and inhibition of ACE-2 binding were lower for beta and gamma RBDs and much lower for omicron RBD. The third vaccination after 6 months strongly increased both the IgG titers and the neutralizing effect against all variants, especially for omicron, leading to 63% ± 13% neutralization potential. Importantly, neutralization linearly increased with the IgG titers. Frontiers Media S.A. 2022-06-15 /pmc/articles/PMC9242094/ /pubmed/35784285 http://dx.doi.org/10.3389/fimmu.2022.915034 Text en Copyright © 2022 Schwarze, Krizsan, Brakel, Pohl, Volke and Hoffmann https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Schwarze, Mandy
Krizsan, Andor
Brakel, Alexandra
Pohl, Fabian
Volke, Daniela
Hoffmann, Ralf
Cross-Reactivity of IgG Antibodies and Virus Neutralization in mRNA-Vaccinated People Against Wild-Type SARS-CoV-2 and the Five Most Common SARS-CoV-2 Variants of Concern
title Cross-Reactivity of IgG Antibodies and Virus Neutralization in mRNA-Vaccinated People Against Wild-Type SARS-CoV-2 and the Five Most Common SARS-CoV-2 Variants of Concern
title_full Cross-Reactivity of IgG Antibodies and Virus Neutralization in mRNA-Vaccinated People Against Wild-Type SARS-CoV-2 and the Five Most Common SARS-CoV-2 Variants of Concern
title_fullStr Cross-Reactivity of IgG Antibodies and Virus Neutralization in mRNA-Vaccinated People Against Wild-Type SARS-CoV-2 and the Five Most Common SARS-CoV-2 Variants of Concern
title_full_unstemmed Cross-Reactivity of IgG Antibodies and Virus Neutralization in mRNA-Vaccinated People Against Wild-Type SARS-CoV-2 and the Five Most Common SARS-CoV-2 Variants of Concern
title_short Cross-Reactivity of IgG Antibodies and Virus Neutralization in mRNA-Vaccinated People Against Wild-Type SARS-CoV-2 and the Five Most Common SARS-CoV-2 Variants of Concern
title_sort cross-reactivity of igg antibodies and virus neutralization in mrna-vaccinated people against wild-type sars-cov-2 and the five most common sars-cov-2 variants of concern
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9242094/
https://www.ncbi.nlm.nih.gov/pubmed/35784285
http://dx.doi.org/10.3389/fimmu.2022.915034
work_keys_str_mv AT schwarzemandy crossreactivityofiggantibodiesandvirusneutralizationinmrnavaccinatedpeopleagainstwildtypesarscov2andthefivemostcommonsarscov2variantsofconcern
AT krizsanandor crossreactivityofiggantibodiesandvirusneutralizationinmrnavaccinatedpeopleagainstwildtypesarscov2andthefivemostcommonsarscov2variantsofconcern
AT brakelalexandra crossreactivityofiggantibodiesandvirusneutralizationinmrnavaccinatedpeopleagainstwildtypesarscov2andthefivemostcommonsarscov2variantsofconcern
AT pohlfabian crossreactivityofiggantibodiesandvirusneutralizationinmrnavaccinatedpeopleagainstwildtypesarscov2andthefivemostcommonsarscov2variantsofconcern
AT volkedaniela crossreactivityofiggantibodiesandvirusneutralizationinmrnavaccinatedpeopleagainstwildtypesarscov2andthefivemostcommonsarscov2variantsofconcern
AT hoffmannralf crossreactivityofiggantibodiesandvirusneutralizationinmrnavaccinatedpeopleagainstwildtypesarscov2andthefivemostcommonsarscov2variantsofconcern